FIELD: medicine.
SUBSTANCE: assessing the acute period when entering the clinic level of markers of inflammation in the blood, IL-6, CRP, TNF-α and instrumental studies of spirography, Holter monitoring of ECG. Then calculating the forecasting coefficient by the formula: Kprogn Dlit=1.19532-0.171896*lechen-0,00392163*CRB+0.000232908*IL_6-0.00328536*FNO-0.00626344*OFB_1+0.00898338*prist_1+0.00282975*dlit_1-0.00522293*kachel+0.000463957*mokrota, where lechen is the type of treatment (1 - standard therapy, 2 - therapy with roflumilast supplementation), CRB - C-reactive protein, measured in venous blood, mg/L, IL_6 - interleukin-6, measured in venous blood, pg/ml, FNO - tumour necrosis factorα, Measured in venous blood, pg/ml, OFB_1 - FEV-1 by spirography, %, prist_1 - the number of attacks of angina pectoris per week on the diary of self-control, dlit_1 - duration of myocardial ischemia per day according to Holter ECG monitoring, kachel - the number of cough pushes per day on the self-monitoring diary; Mokrota - the amount of sputum produced per day by self-monitoring diary, ml, and at KprognDlit 0.63 or more the effectiveness of standard therapy including berodual, dexamethasone, ceftriaxone, euphyllin, high and additional prescription of medications is not required; When detecting KProGnDlit less than when KprognDlit is detected, less than 0.63 standard therapy will not give the proper effect and it will be necessary to add roflumilast.
EFFECT: use of the method makes it possible to predict the effectiveness of the anti-inflammatory therapy scheme with high accuracy even before its practical application in patients with COPD in combination with IHD.
2 tbl
